Siemens Healthineers AG

  • WKN: SHL100
  • ISIN: DE000SHL1006
  • Land: Deutschland

Nachricht vom 11.10.2021 | 15:00

Siemens Healthineers AG: Release of a capital market information

Siemens Healthineers AG / Disclosure pursuant to Art. 5 para. 1 lit. b), para. 3 of the Regulation (EU) no. 596/2014 (MAR) in conjunction with Art. 2 para. 2, para. 3 of the Delegated Regulation (EU) No. 2016/1052 Share buyback - 15th Interim Reporting
11.10.2021 / 15:00
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure pursuant to Art. 5 para. 1 lit. b), para. 3 of the Regulation (EU) no. 596/2014 (MAR) in conjunction with Art. 2 para. 2, para. 3 of the Delegated Regulation (EU) No. 2016/1052

Share buyback - 15th Interim Reporting

In the time period from and including 04 October 2021 until and including 08 October 2021, a number of 164,429 shares of Siemens Healthineers AG were bought back within the framework of the share buyback of Siemens Healthineers AG; on 23 June 2021, Siemens Healthineers AG disclosed pursuant to Art. 5 para. 1 lit. a) of the Regulation (EU) No. 596/2014 (MAR) in conjunction with Art. 2 para. 1 of the Delegated Regulation (EU) No. 2016/1052 the start of the share buyback on 28 June 2021.

Shares were bought back as follows:

Day of purchase Aggregated volume of shares Weighted average price (EUR)1
10/04/2021 10,000 55.3030
10/05/2021 15,000 55.6792
10/06/2021 89,429 54.8855
10/07/2021 45,000 55.2253
10/08/2021 5,000 55.4812
 

The transactions are published in a detailed form on the website of Siemens Healthineers AG (www.corporate.siemens-healthineers.com/investor-relations).

The total volume of shares which were bought back within the framework of the share buyback in the time period from and including 28 June 2021 until and including 08 October 2021 amounts to 2,303,939 shares.

The purchase of the shares of Siemens Healthineers AG is carried out by a credit institution that has been commissioned by Siemens Healthineers AG; the shares are repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA).

Munich, 11 October 2021

Siemens Healthineers AG

The Managing Board

1 Excluding incidental acquisition costs, rounded to four decimal places according to commercial practice.



11.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021